Risk of digoxin intoxication caused by clarithromycin-digoxin interactions in heart failure patients: a population-based study
- PMID: 19655133
- DOI: 10.1007/s00228-009-0698-4
Risk of digoxin intoxication caused by clarithromycin-digoxin interactions in heart failure patients: a population-based study
Abstract
Objective: To quantify the effect of exposures to digoxin–clarithromycin interactions on the risk of digoxin toxicity requiring hospitalizations in a population-based manner in a Taiwanese population.
Methods: This is a retrospective population-based nested case–control study. Data were retrieved from the National Health Insurance Research Database. Heart failure (HF) patients newly treated with digoxin between 1 January 2001 and 31 December 2004 were retrieved from the database as the study cohort. Case patients, admitted to the hospitals with the diagnosis of digoxin intoxication (ICD-9 code 972.1) were identified from the study cohort and compared with the matched controls for the receipt of clarithromycin.
Results: A total of 154,058 patients were identified as the study cohort; from these, 595 cases and 27,020 matched controls were selected for study. The prescription of clarithromycin at 7, 14, and 30 days prior to the index date was associated with a 4.36- (95% CI 1.28–14.79), 5.07- (95% CI 2.36–10.89), and 2.98-fold (95% CI 1.59–5.63) increase in hospitalization for digoxin intoxication, respectively. The results of the dose–response relationship also indicated that clarithromycin prescribed with a prescribed daily dose (PDD)/defined daily dose (DDD) ratio >2 led to a 55.41-fold (95% CI 9.31–329.9) increase of the risk, which is significantly greater than that prescribed with a 1–2 PDD/DDD ratio (adjusted OR 4.81; 95% CI 1.88–12.30) or with a <1 PDD/DDD ratio (adjusted OR 0.78; 95% CI 0.19–3.20).
Conclusion: This study provides empirical evidence that digoxin–clarithromycin interactions do increase the risk of hospitalization for digoxin intoxication in HF patients and that this risk could reach as high as 55.4-fold. We strongly recommend that the combined use of digoxin with clarithromycin should be avoided and that digoxin concentrations should be monitored closely in situations where the combination can not be avoided.
Similar articles
-
Risk of digoxin intoxication in heart failure patients exposed to digoxin-diuretic interactions: a population-based study.Br J Clin Pharmacol. 2010 Aug;70(2):258-67. doi: 10.1111/j.1365-2125.2010.03687.x. Br J Clin Pharmacol. 2010. PMID: 20653679 Free PMC article.
-
Concomitant digoxin toxicity and warfarin interaction in a patient receiving clarithromycin.Ann Pharmacother. 1999 Jul-Aug;33(7-8):796-9. doi: 10.1345/aph.18330. Ann Pharmacother. 1999. PMID: 10466907
-
Macrolides, Digoxin Toxicity and the Risk of Sudden Death: A Population-Based Study.Drug Saf. 2017 Sep;40(9):835-840. doi: 10.1007/s40264-017-0539-9. Drug Saf. 2017. PMID: 28421551
-
Clarithromycin-induced digoxin toxicity: a case report and a review of the literature.Conn Med. 2001 Sep;65(9):527-9. Conn Med. 2001. PMID: 11678058 Review.
-
Use of digoxin for heart failure and atrial fibrillation in elderly patients.Am J Geriatr Pharmacother. 2010 Oct;8(5):419-27. doi: 10.1016/j.amjopharm.2010.10.001. Am J Geriatr Pharmacother. 2010. PMID: 21335295 Review.
Cited by
-
Population pharmacokinetics of digoxin in elderly patients.Eur J Drug Metab Pharmacokinet. 2013 Jun;38(2):115-21. doi: 10.1007/s13318-012-0107-8. Epub 2012 Oct 25. Eur J Drug Metab Pharmacokinet. 2013. PMID: 23096939
-
Clinical Relevance of Drug-Drug Interactions With Antibiotics as Listed in a National Medication Formulary: Results From Two Large Population-Based Case-Control Studies in Patients Aged 65-100 Years Using Linked English Primary Care and Hospital Data.Clin Pharmacol Ther. 2023 Feb;113(2):423-434. doi: 10.1002/cpt.2807. Epub 2022 Dec 16. Clin Pharmacol Ther. 2023. PMID: 36448824 Free PMC article.
-
Risk of digoxin intoxication in heart failure patients exposed to digoxin-diuretic interactions: a population-based study.Br J Clin Pharmacol. 2010 Aug;70(2):258-67. doi: 10.1111/j.1365-2125.2010.03687.x. Br J Clin Pharmacol. 2010. PMID: 20653679 Free PMC article.
-
Improving antibacterial prescribing safety in the management of COPD exacerbations: systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients.J Antimicrob Chemother. 2019 Oct 1;74(10):2848-2864. doi: 10.1093/jac/dkz221. J Antimicrob Chemother. 2019. PMID: 31127283 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous